On January 13, 2020, ENDRA Life Sciences Inc. (the Company) entered into Amendment 3 (the Amendment) to that certain Collaborative Research Agreement between the Company and General Electric Company (GE), dated as of April 22, 2016, as amended by that certain Amendment 1 to Collaborative Research Agreement, dated April 21, 2017, and by that certain Amendment 2 to Collaborative Research Agreement, dated January 30, 2018. The Amendment extends the term of the Agreement to January 14, 2021 and modifies certain rights of first offer held by GE with respect to manufacturing and licensing rights for the Company's Thermo-Acoustic Enhanced Ultrasound technology for use in a fatty liver disease application.